hematologic cancers

Related by string. * Hematologic : hematologic toxicity correlated . hematologic malignancies . hematologic toxicity . Hematologic Malignancies . hematologic toxicities . common hematologic malignancy . hematologic adverse reactions / Cancers . CANCERS : skin cancers . colon cancers . Gastrointestinal Cancers Symposium . lung cancers . hematological cancers notably . prostate cancers * *

Related by context. All words. (Click for frequent words.) 72 tumor malignancies 71 hematological malignancies 69 hematologic malignancies 68 hematological cancers 66 heavily pretreated 66 hematological tumors 66 hematologic tumors 63 histologies 63 lymphoid tumors 63 leukemia AML 63 ATC ovarian cancer 63 HER2 positive metastatic breast 63 alvespimycin 63 refractory chronic lymphocytic 63 TRAIL receptor antibodies 62 sarcoma melanoma 62 haematological cancers 62 essential thrombocythemia 62 haematological malignancies 62 CYT# potent vascular disrupting 62 myeloproliferative disorders 62 myeloproliferative diseases 62 lintuzumab SGN 62 TTR amyloidosis 62 lymphoid malignancies 62 orally administered inhibitor 62 imatinib Gleevec ® 62 PXD# 61 Azedra 61 preclinical xenograft models 61 RGB # 61 essential thrombocythemia ET 61 relapsed multiple myeloma 61 Crohn disease CD 61 JAK1 61 solid tumors 61 sorafenib Nexavar ® 61 MEK inhibitors 61 investigational monoclonal antibody 61 HGS ETR1 61 pediatric acute lymphoblastic 61 hematological 61 refractory AML 61 non metastatic osteosarcoma 60 erlotinib Tarceva ® 60 Annamycin 60 myelodysplastic syndromes MDS 60 myelofibrosis polycythemia vera 60 Evoltra ® 60 relapsed refractory multiple myeloma 60 leukemia ALL 60 demonstrated antitumor activity 60 oncology therapeutics 60 prokinetic agent 60 epithelial tumors 60 gastric pancreatic 60 acute leukemias 60 TTF Therapy 60 standard chemotherapy regimens 60 receptor tyrosine kinase inhibitor 60 hypereosinophilic syndrome 60 hematologic malignancy 60 glioblastoma multiforme GBM 60 neovascular diseases 59 Acute Myeloid Leukemia AML 59 refractory metastatic 59 hematological diseases 59 cancer mCRC 59 metastatic renal 59 tumor xenograft models 59 anti leukemic 59 hematological indications 59 xenograft models 59 tubulin inhibitor 59 HGS ETR2 59 hematologic disorders 59 bavituximab monotherapy trial 59 systemic anaplastic large 59 relapsed leukemia 59 Hsp# inhibition 59 radezolid 59 ALN PCS 59 advanced metastatic renal 59 gastrointestinal disorders ATI 59 malignant lymphomas 59 relapsed MM 59 CD# expressing 59 cognitive impairment associated 59 kinase inhibition 59 histological subtypes 59 novel VDA molecule 59 kidney urologic 59 refractory multiple myeloma 59 CCR9 antagonist 59 Kit CD# positive 59 Carfilzomib 59 oral picoplatin 59 CTAP# Capsules 59 recurrent glioblastoma multiforme 59 cell lymphoma CTCL 59 rALLy 59 HGS# 59 Solazed TM 59 recurrent glioblastoma 59 rheumatoid arthritis psoriatic arthritis 59 Akt inhibitor 58 AML acute myeloid 58 neuroendocrine cancers 58 dasatinib Sprycel 58 JAK2 inhibitor 58 Phase #b/#a clinical 58 chronic eosinophilic leukemia 58 Omacetaxine 58 Virulizin ® 58 refractory CLL 58 ENMD # 58 forodesine 58 hematopoietic malignancies 58 talactoferrin 58 Exelixis compounds 58 atypical hemolytic uremic syndrome 58 MabThera Rituxan 58 myeloproliferative neoplasms 58 FOLFOX6 chemotherapy regimen 58 IMC A# 58 PRTX 58 LHRH receptor positive 58 ovarian breast 58 pan HDAC inhibitor 58 malignancies 58 LymphoStat B belimumab 58 squalamine 58 leukaemias 58 VEGFR2 inhibitor 58 INCB# [003] 58 liver cancers hypercholesterolemia 58 dose escalation Phase 58 bevacizumab Avastin ® 58 cMET 58 Acute lymphoblastic leukemia 58 ganetespib 58 chronic lymphocytic leukemia CLL 58 hematologic 58 liver cancers TTR 58 MDV# 58 rheumatologic 58 oral prodrug 58 advanced medullary thyroid 58 relapsed refractory 58 investigational compounds 57 Myelodysplastic syndromes MDS 57 multiple sclerosis rheumatoid arthritis 57 Aplidin 57 systemic ALCL 57 metastatic pancreatic 57 deforolimus 57 Squalamine 57 Acute myeloid leukemia AML 57 Chronic lymphocytic leukemia CLL 57 castrate resistant prostate cancer 57 catheter occlusion 57 familial amyloidotic polyneuropathy FAP 57 non splenectomized 57 mixed dyslipidemia 57 Hsp# inhibitors 57 FGFR 57 refractory NSCLC 57 metastatic renal cell 57 LHRH antagonists 57 Xanafide 57 acute myelogenous leukemia AML 57 AEG# 57 sunitinib malate 57 relapsed SCLC 57 hematological disorders 57 gastrointestinal stromal tumor GIST 57 nonsmall cell lung cancer 57 MCSP respectively 57 evaluating tivozanib 57 PEG SN# 57 Panzem R NCD 57 malignant pheochromocytoma 57 systemic fungal infections 57 medullary thyroid cancer 57 axitinib 57 colorectal lung 57 hA# 57 vidofludimus 57 imatinib Gleevec 57 motesanib 57 VEGF receptors 57 leukemias 57 selective kinase inhibitor 57 resistant ovarian cancer 57 indolent follicular non 57 CD# CEA 57 JAK inhibitors 57 anti angiogenic agents 57 PI3K/Akt pathway inhibitor 57 refractory acute myeloid 57 acute GvHD 57 YONDELIS 57 haematological 57 Troxatyl 57 investigational therapies 57 Aurora kinase 57 basal cell nevus syndrome 57 vinca alkaloid 57 PNP inhibitor 57 entinostat 57 Symadex 57 metastatic HRPC 57 pediatric neuroblastoma 57 Acute myelogenous leukemia 57 enzastaurin 57 anti fibrotic 57 ponatinib 57 smoldering myeloma 57 onset diabetes mellitus 57 Alessandro Riva 57 TACI Ig 57 papillary renal cell carcinoma 57 HGS ETR1 mapatumumab 57 eosinophilic asthma 57 metastatic bladder 57 B CLL 57 Tamibarotene 57 lymphocytic leukemia 57 CCX# 57 systemic juvenile idiopathic 57 Seliciclib 57 pancreatic colon 57 myelofibrosis MF 57 BR.# 57 ovarian carcinoma 57 advanced carcinoid 57 adhesion molecule EpCAM expressing 57 signal transduction inhibitors 57 serologically active systemic lupus 57 Imprime PGG 57 ON #.Na 57 multiple myeloma MM 57 leukemia CLL 57 candidates Azedra TM 57 potent antiproliferative 56 myelofibrosis 56 cetuximab Erbitux R 56 recurrent NSCLC 56 Voreloxin 56 refractory metastatic colorectal cancer 56 tumor subtypes 56 metastatic CRC 56 ongoing Phase 1b 56 prostate pancreatic 56 imatinib resistant 56 refractory gout 56 malignant gliomas 56 ocular formulation 56 Gleevec resistant 56 HRPC 56 ALN TTR# 56 EGFR HER2 56 haematologic malignancies 56 pancreatic NET 56 hematological malignancy 56 radiation sensitizer 56 follicular NHL 56 immunological diseases 56 evaluating mipomersen 56 acyclovir Lauriad R 56 Perifosine 56 Genasense ® 56 lupus nephritis 56 TRAIL R1 56 Ceflatonin 56 indolent NHL 56 OXi# 56 antibody MAb 56 previously untreated follicular 56 taxane resistant 56 paclitaxel Taxol ® 56 rALLy clinical trial 56 lymphoma leukemia 56 MGd 56 platinum refractory 56 Cloretazine 56 Glioblastomas 56 evaluating REVLIMID 56 dermatofibrosarcoma protuberans 56 AP# [003] 56 Selzentry Celsentri 56 retinal disorders 56 lung prostate 56 multi kinase inhibitor 56 virus HCV infection 56 rheumatoid arthritis psoriasis 56 metastatic kidney 56 Cutaneous T 56 osteosarcoma Ewing sarcoma 56 gastrointestinal mucositis 56 ELACYT 56 GRN#L 56 AVN# Phase 56 metaglidasen 56 Acute Myelogenous Leukemia AML 56 pancreatic adenocarcinoma 56 refractory indolent non 56 Atiprimod 56 Carcinoid tumors 56 metastatic GIST 56 tyrosine kinase inhibitors 56 Surgical resection 56 favorable pharmacokinetic profile 56 follicular non 56 Chronic lymphocytic leukemia 56 myelodysplastic syndrome MDS 56 refractory CTCL 56 Fludara ® 56 OMP #R# 56 formerly LymphoStat B 56 phase IIb clinical 56 CA4P 56 galiximab 56 L Annamycin 56 KRAS mutant 56 leukemias lymphomas 56 lymphoma CTCL 56 cell malignancies 56 acute myeloid leukemia AML 56 Myelodysplastic syndromes 56 proliferative diseases 56 docetaxel Taxotere ® 56 sodium thiosulfate STS 56 diabetic neuropathic pain 56 Smac mimetics 56 vaccine GRNVAC1 56 lung pancreatic 56 vascular disrupting agent 56 cutaneous T cell 56 panobinostat 56 diseases fat malabsorption 56 cutaneous T 56 nilotinib Tasigna ® 56 SPRYCEL ® 56 relapsed Acute Myeloid 56 CINQUIL 56 Ganetespib 56 Phase Ib II 56 cilengitide 56 lomitapide 56 sunitinib Sutent ® 56 breast pancreatic 56 Basal cell 56 ara C 56 lenalidomide Revlimid R 56 circulating endothelial cells 56 Fludarabine 55 osteolytic bone disease 55 phase IIb study 55 relapsed refractory ALL 55 mediated amyloidosis ATTR hypercholesterolemia 55 proteasome inhibitor 55 antiangiogenesis therapies 55 ALN TTR 55 Vidaza ® 55 relapsed refractory AML 55 OHR/AVR# 55 pomalidomide 55 Phase #/#a trial 55 histologic subtype 55 BRAF inhibitor 55 null responder 55 ocular disorders 55 lymphoproliferative disorders 55 squamous 55 INCB# [001] 55 NovaBay Aganocide compounds 55 HCV genotypes 55 tumors GIST 55 ovarian lung 55 class mGluR5 inhibitor 55 HQK 55 heavily pretreated patients 55 ospemifene 55 peptibody 55 MEK inhibitor RDEA# 55 Blinatumomab 55 carcinoid 55 Triapine 55 ThermoDox R 55 relapsed acute lymphoblastic 55 sodium glucose cotransporter 55 KRAS mutations occur 55 OncoVEX GM CSF 55 Ribavirin causes 55 GRN# 55 recurrent malignant glioma 55 unresectable tumors 55 NEUVENGE 55 HCV polymerase inhibitors 55 sorafenib tablets 55 novel histone deacetylase 55 carcinoma HCC 55 taxane refractory 55 Genasense evaluating 55 acute promyelocytic leukemia APL 55 IAP inhibitor 55 vinca alkaloids 55 unstable angina UA 55 targeting CD# 55 TELINTRA 55 chronic myeloid 55 depsipeptide 55 PNH patients 55 lymphoma Hodgkin lymphoma 55 HBeAg negative 55 diabetic retinopathy DR 55 therapeutic regimens 55 Medullary thyroid cancer 55 metastatic castration resistant 55 Hepatocellular Carcinoma HCC 55 cyclin dependent kinases CDKs 55 riociguat 55 neoplastic 55 Romidepsin 55 grade gliomas 55 Ceflatonin R 55 trial evaluating PRX# 55 thalidomide Thalomid 55 Preclinical studies suggest 55 autoantibody positive 55 calcineurin inhibitors 55 elacytarabine 55 Neuradiab 55 hepatitis C HCV 55 RCW breast cancer 55 stage IIIB IV 55 radiochemotherapy 55 lymphomas leukemias 55 BCR ABL inhibitors 55 RNAi therapeutic targeting PCSK9 55 BAY #-# 55 neuro inflammatory 55 erythematosus SLE 55 haematologic 55 Bayer HealthCare Onyx Pharmaceuticals 55 HER2 positive cancers 55 Cloretazine ® 55 XL# XL# XL# XL# 55 IMC #B 55 antimitotic 55 pertuzumab 55 acetonide FA 55 pancreatic prostate 55 myeloproliferative neoplasms MPNs 55 neuroendocrine tumors 55 TREANDA 55 T#I mutant 55 follicular lymphoma FL 55 ARRY # 55 Diabetic Macular Edema 55 basal cell carcinoma BCC 55 ENMD 55 immune dysregulation 55 gastroenterology neurology 55 including eniluracil ADH 55 dasatinib Sprycel ® 55 huN# DM1 55 huC# DM4 55 potentially hepatotoxic 55 sarcomatoid 55 metastatic neuroendocrine tumors 55 polycythemia vera essential thrombocythemia 55 Benlysta belimumab 55 JAK2 inhibitors 55 diabetic nephropathy 55 docetaxel Taxotere R 55 aflibercept VEGF Trap 55 Allovectin 7 ® 55 chronic myelogenous leukemia CML 55 esophageal candidiasis 55 renal cell carcinoma 55 HDAC Inhibitor 55 constipation OIC 55 psoriasis rheumatoid arthritis 55 histone deacetylase HDAC inhibitor 55 Cloretazine R 55 de novo kidney transplant 55 BCR ABL inhibitor 55 anti angiogenic therapy 55 metastatic RCC 55 protein kinase inhibitors 55 EGFr 55 Golimumab 55 superficial bladder cancer 55 androgen independent 55 chemo resistant 55 EGFR inhibitors 55 advanced metastatic prostate 55 MEK inhibitor 55 ALN VSP 55 JMML 55 Metastatic Melanoma 55 renal cell carcinomas 55 Elotuzumab 55 AKT inhibitor 54 cell lymphomas 54 Entereg R 54 proliferative diabetic retinopathy 54 receiving TNF blockers 54 cytokine refractory 54 imetelstat 54 ALN HTT 54 alpha folate receptor 54 antagomirs 54 Azixa 54 APOPTONE 54 Diffuse Large B 54 lipid lowering therapies 54 farletuzumab 54 Combivir Kivexa 54 cediranib 54 CLL SLL 54 TLR8 agonist 54 IMA# 54 Sudhir Agrawal D.Phil 54 metastatic melanoma 54 investigational humanized monoclonal antibody 54 PDX pralatrexate 54 idiopathic thrombocytopenic purpura 54 colorectal breast 54 Mantle Cell Lymphoma 54 ruxolitinib 54 refractory cutaneous T 54 polymerase inhibitors 54 metastatic renal cell carcinoma 54 cyclophilin inhibitors 54 LEUKINE 54 lymphomas 54 generation purine nucleoside 54 infectious diseases autoimmune diseases 54 obatoclax 54 diagnostic biomarkers 54 immunotherapeutic approaches 54 anthracycline taxane 54 Targretin 54 metastatic malignant melanoma 54 XL# XL# 54 fibrotic disease 54 coagulation disorders 54 trastuzumab Herceptin R 54 lysosomal storage disorders 54 SAR# [004] 54 aHUS 54 velafermin 54 pharmacological chaperone compounds 54 multitargeted 54 superficial basal cell carcinoma 54 crizotinib PF # 54 MAGE A3 ASCI 54 decompensated liver disease 54 retinal vein occlusion induced 54 relapsed AML 54 Darinaparsin 54 sorafenib Nexavar 54 MOZOBIL 54 proliferative retinopathy 54 hepatic encephalopathy HE 54 CIMZIA ™ 54 Combo Stent 54 oral JAK1 54 IAP inhibitors 54 GEM OS2 54 Archexin 54 Vidofludimus 54 JAK#/JAK# inhibitor CYT# 54 randomized Phase 2b 54 commercialize deforolimus 54 seliciclib 54 antimetabolite 54 tanespimycin 54 synthetic retinoid 54 inflammatory autoimmune diseases 54 Cerashield 54 kinase inhibitor 54 Aflibercept 54 non squamous histology 54 trans retinoic acid ATRA 54 gastric carcinoma 54 osteosarcomas 54 atypical Hemolytic Uremic Syndrome 54 gastro intestinal inflammation 54 Panzem R 54 PDE# inhibitors 54 leukemia lymphoma multiple myeloma 54 lintuzumab 54 pheochromocytoma 54 relapsed ALL 54 JAK inhibitor 54 relapsed ovarian cancer 54 neutropenia dehydration dyspnea 54 ovarian prostate 54 novel immunotherapies 54 Cannabinor 54 unfavorable cytogenetics 54 isoform selective 54 relapsing remitting MS RRMS 54 eculizumab 54 ASONEP 54 decitabine 54 Cloretazine R VNP#M 54 dirucotide MBP# 54 liposomal formulation 54 differentiated thyroid 54 Relapsed Refractory 54 cisplatin resistant 54 M2 subunit 54 fungoides 54 MGCD# [001] 54 thetreatment 54 ganaxolone 54 rheumatoid arthritis Crohn disease 54 CBLC# 54 mTOR inhibitors 54 protein kinase inhibitor 54 refractory colorectal cancer 54 anticancer therapy 54 Sym# 54 EGFR mutations 54 Ph + ALL 54 FOLOTYN ® 54 K ras mutations 54 Alzhemed TM 54 MPS IVA 54 carcinoid tumors 54 immuno inflammatory diseases 54 diagnostic molecular imaging 54 renal tumors 54 SinuNase TM 54 papillary 54 paclitaxel Taxol R 54 Hsp# Inhibitor 54 hematopoietic 54 squamous cell lung cancer 54 preclinical compounds 54 orally bioavailable 54 targeted radiotherapeutics 54 inhibiting tumor 54 hematopoietic cancers 54 Clofarabine 54 Acute myeloid leukemia 54 PI3K inhibitors 54 extracranial 54 Deforolimus 54 glufosfamide 54 squamous cell histology 54 molecular abnormalities 54 immune modulators 54 TTR gene 54 hypoxia inducible factor 54 posterior uveitis 54 COU AA 54 Bezielle 54 leukemia CML 54 p# inhibitor 54 BrachySil TM 54 non squamous 54 metastatic lesions 54 SJIA 54 acute myeloid 54 transthyretin TTR mediated amyloidosis 54 chronic HCV infection 54 MGUS 54 VEGF inhibitors 54 lymphoma subtypes 54 Zoraxel 54 taxane chemotherapy 53 immunomodulatory 53 uric acid lowering 53 remission induction 53 BRAF V# mutation 53 pathophysiological effects 53 metastatic colorectal 53 alefacept 53 immune modulating 53 systemic lupus erythematosus lupus 53 refractory angina 53 MCyR 53 soft tissue sarcomas 53 Sezary syndrome 53 dosing cohort 53 registrational 53 darinaparsin Zinapar TM 53 YONDELIS R 53 Brentuximab Vedotin SGN 53 Relapsing remitting MS 53 blinded randomized placebo controlled 53 Telintra 53 inflammatory autoimmune 53 KRAS wild 53 hepatorenal syndrome 53 clinical trials SGN 53 secondary hyperparathyroidism 53 hypoparathyroidism 53 immuno modulatory 53 CINTREDEKIN BESUDOTOX 53 Crohn colitis 53 metastatic hormone refractory 53 pediatric malignancies 53 TG# [003] 53 rituximab refractory 53 Colon polyps 53 zanolimumab 53 RNAi therapeutic targeting 53 ceftazidime 53 Insegia 53 HCV protease 53 ErbB2 positive 53 diagnosed glioblastoma multiforme 53 R sorafenib tablets 53 diagnosed Ph + 53 progressive PsA 53 rituximab refractory follicular 53 neratinib 53 anthracycline containing 53 prostate cancer CRPC 53 colorectal carcinoma 53 CR# vcMMAE 53 OMNARIS HFA 53 placebo controlled Phase 53 medically inoperable 53 Hodgkin lymphoma HL 53 anticancer therapies 53 skeletal muscle weakness 53 R Saizen R 53 metastatic CRPC 53 CHOP chemotherapy 53 Vitaxin 53 registrational trial 53 antiangiogenic activity 53 leukemia myeloma 53 bortezomib Velcade R 53 mediated autoimmune diseases 53 antitumor activity 53 trastuzumab Herceptin ® 53 herpetic keratitis 53 P#X# antagonist 53 chronic periodontitis 53 castrate resistant 53 factor TNF 53 Follicular lymphoma 53 tyrosine kinase inhibitor TKI 53 GERD migraine headaches 53 hormone refractory prostate cancer 53 compound INCB# 53 gastrointestinal stromal tumor 53 Acute Myeloid Leukemia 53 gastrointestinal cancers 53 BRIM3 53 rheumatoid arthritis multiple sclerosis 53 allogeneic stem cell 53 paclitaxel eluting stents 53 derivatives Radilex TM 53 metastatic liver 53 follicular lymphomas 53 Sapacitabine 53 hypophosphatasia 53 GISTs 53 myelodysplastic syndromes 53 GRNOPC1 contains 53 biliary tract cancer 53 ASG 5ME 53 stage IIIb 53 HuLuc# 53 immunodeficiencies 53 anticancer agents 53 nonmelanoma 53 PKC# 53 neuropathic pain metabolic diseases 53 EndoTAGTM 1 53 demyelinating diseases 53 T1DM 53 relapsing remitting 53 TNF alpha antagonist 53 idiopathic thrombocytopenic purpura ITP 53 keloid scarring 53 BRIM2 53 vascular disrupting agents 53 BiTE antibody 53 2 methoxyestradiol 53 clofarabine 53 fusion enhancers 53 juvenile idiopathic arthritis JIA 53 TNF blocking 53 lenalidomide dexamethasone 53 Amrubicin 53 A3 adenosine receptor 53 non alcoholic steatohepatitis 53 Chronic Myeloid Leukemia 53 hormone refractory metastatic prostate 53 grade cervical intraepithelial 53 gastrointestinal malignancies 53 NSCLC 53 Hedgehog signaling pathway 53 chemotherapy regimens 53 volociximab 53 Vidaza azacitidine 53 XmAb# 53 selective inhibitor 53 Campath ® 53 tumor metastases 53 squamous histology 53 colorectal liver metastases 53 GED aPC 53 Apoptone 53 2 inhibitor CYT# 53 histologically confirmed 53 targeted radiotherapeutic 53 dimebon latrepirdine 53 cannabinor 53 hematopoietic stem cell 53 Pimavanserin 53 mapatumumab 53 mGluR2 NAM 53 recurrent metastatic ovarian cancer 53 Tasimelteon 53 telomerase inhibition 53 XL# inhibits 53 Chronic Lymphocytic Leukemia CLL 53 refractory acute lymphoblastic 53 Hurler syndrome 53 inflammatory diseases 53 prostate cancer HRPC 53 visceral metastases 53 preclinical models 53 doublet chemotherapy 53 stage IIIb IV 53 unresectable locally advanced 53 elotuzumab 53 polycythemia vera PV 53 cells hESCs 53 tiuxetan 53 belinostat 53 cell acute lymphoblastic 53 acute coronary syndromes ACS 53 Gliomas 53 BCG refractory carcinoma 53 leading oral taxane 53 PD LID 53 cardio renal 53 herpes zoster shingles 53 GALNS 53 INSPIRE Trial Phase III 53 mRCC 53 Doxil ® 53 juvenile myelomonocytic leukemia 53 Acute Myeloid Leukaemia AML 53 delta gamma agonist 53 LHRH analogues 53 mitogen activated ERK kinase 53 untreated multiple myeloma 53 advanced hepatocellular carcinoma 53 Pathway Inhibitor 53 autoimmune uveitis 53 hematologic diseases 53 hoFH patients 53 colorectal pancreatic 53 delta isoform 53 skeletal metastases 53 vaccines oncolytic virus 53 dose cohorts 53 T#I mutation 53 complement inhibitor eculizumab 53 IMiDs ® compound 53 rheumatoid arthritis lupus 53 IMGN# 53 CD# antibody [001] 53 EGFR tyrosine kinase inhibitors 53 intravesical therapy 53 unresectable 53 mutated KRAS gene 53 non squamous NSCLC 53 virus HBV infection 53 rheumatoid arthritis thrombocytopenia 53 gemcitabine Gemzar 52 recurrent glioblastoma multiforme GBM 52 EGFR mutation positive 52 refractory anaplastic astrocytoma 52 castration resistant prostate cancer 52 stage IIIB 52 CYT# vascular disrupting 52 antitumour activity 52 CIMZIA TM certolizumab pegol 52 glioblastoma 52 hepatocellular cancer 52 pulmonary hypertension PH 52 allogeneic HSCT 52 HDACi 52 peritoneal carcinomatosis 52 interferon IFN 52 pediatric glioma 52 Zolinza 52 serous ovarian cancer 52 antimetastatic activity 52 immunologic diseases 52 anti EGFR antibody 52 novel peptide 52 bexarotene 52 mycosis fungoides 52 gastrointestinal stromal tumors 52 novel peptide therapeutics 52 visilizumab 52 receptor inhibitor 52 chronic immune thrombocytopenic 52 Gleevec imatinib mesylate 52 GAP #B# 52 hypoxia activated prodrug 52 AQ4N 52 nonmyeloablative 52 histological subtype 52 Janus Kinase 52 HspE7 52 cytotoxics 52 Synovial sarcoma 52 Philadelphia Chromosome Positive 52 Vicinium TM 52 targeting PCSK9 52 Shigamabs ® 52 nucleoside 52 tamibarotene 52 systemic lupus erythematosus SLE 52 Glioblastoma multiforme GBM 52 small molecule tyrosine 52 PI3K/mTOR 52 Behcet uveitis 52 Pemetrexed 52 TroVax ® 52 TÎ ² 4 52 omacetaxine mepesuccinate 52 ZACTIMA 52 reversing heparin 52 chronic myeloid leukemia CML 52 psoriasis Crohn disease 52 adecatumumab 52 medulloblastoma 52 autologous cellular therapies 52 Tarvacin TM 52 chronic HCV 52 purpura ITP 52 Friedreich Ataxia FRDA 52 RezularTM 52 situ CIS 52 Nicole Onetto MD 52 dexanabinol 52 refractory chronic myeloid 52 ocular diseases 52 Hedgehog pathway 52 Fibromyalgia Syndrome FMS 52 Chronic Myeloid Leukemia CML 52 homozygous familial hypercholesterolemia 52 Cetrorelix 52 carcinoma mCRC 52 oral antidiabetic agents 52 ostarine 52 Viprovex TM 52 anemias 52 IRX 2 52 atherothrombosis 52 samalizumab 52 ZOLINZA 52 Li Fraumeni 52 TNF blocker therapy 52 low dose cytarabine 52 leukemia APL 52 pediatric Crohn disease 52 TLR9 agonists 52 Myelodysplastic Syndrome MDS 52 Dacogen injection 52 neurofibromas 52 metastatic uveal melanoma 52 MTP inhibitor 52 metastatic castrate resistant 52 Campath alemtuzumab 52 ophthalmic diseases 52 VitiGam 52 lumiliximab 52 bladder ovarian 52 GvHD 52 fosbretabulin 52 ER CHOP 52 HDAC inhibition 52 premalignant 52 mTOR inhibitor 52 fibrotic diseases 52 AGILECT R 52 EOquin TM 52 monoclonal antibody therapies 52 Marqibo 52 Genentech Rituxan

Back to home page